Home » Topics » BioWorld Science

BioWorld Science
RSS

Roxane Laboratories has begun U.S. nevirapine distribution

Aug. 23, 1996

SR-3775: Promising candidate for cytomegalovirus disease treatment

Aug. 23, 1996

GEM-132 enters phase I safety and pharmacokinetic trial

Aug. 23, 1996

SmithKline Beecham describes protease inhibitors

Aug. 23, 1996

Isis now fully owns fomivirsen

Aug. 23, 1996

Solvay to copromote Famvir in U.S.

Aug. 23, 1996

Vistide marketing collaboration established

Aug. 23, 1996

Sequus and Torrex Pharma sign Amphotec marketing agreement

Aug. 23, 1996

Xoma granted permission to commence phase III for rBPI21

Aug. 23, 1996

Parke-Davis and Xenova begin evaluation of novel antibacterial

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...